Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 433 across all filing types
Latest filing 2026-04-14 Capital/Financing Update
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Board Meeting — Buyback
Capital/Financing Update Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a forthcoming Board of Directors meeting to consider and approve a proposal for a buyback of the company's equity shares. It references compliance with SEBI regulations and the Companies Act, indicating it is an official announcement related to capital structure changes. The document does not contain financial statements or detailed financial data but serves as an intimation of a corporate action (share buyback). The document length is short (2240 characters), and it is clearly an announcement rather than a full report. Therefore, it fits the category of a Capital/Financing Update (CAP).
2026-04-14 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-04-14 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-06 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter from Windlas Biotech Limited addressed to stock exchanges (BSE and NSE) informing about the closure of the trading window in accordance with the company's code of conduct. It specifies the trading window closure period around the release of the financial results for the year ended March 31, 2026. The document does not contain any financial data, results, or detailed report but is an announcement related to compliance and trading restrictions. It is short (1397 characters) and serves as a regulatory notification rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance announcements that do not fit other specific categories.
2026-03-25 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a detailed communication from Windlas Biotech Limited to stock exchanges regarding the results of a postal ballot. It includes voting results for the re-appointment of directors, the scrutinizer's report pursuant to Sections 108 and 110 of the Companies Act, 2013, and related procedural details. The content focuses on the official announcement of voting results from a shareholder postal ballot, including special resolutions passed for director re-appointments. There are no financial statements or management discussion of financial results, so it is not an Annual Report or Interim Report. It is not a proxy solicitation or AGM information, but specifically the official declaration of voting results from a postal ballot. Therefore, the document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA). The document length and detail confirm it is the actual voting results announcement, not just a brief notice or report publication announcement. Confidence is high due to the clear presence of voting results and scrutinizer report.
2026-03-20 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing them about the allotment of equity shares under two Employee Stock Option Schemes. It specifies the number of shares allotted under each scheme and requests the exchanges to take the information on record. The content is an announcement related to share allotment under employee stock option plans, which is a capital change event. The document is short (1532 characters) and does not contain financial statements or detailed financial analysis. Therefore, it is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement or certification. The subject clearly relates to share allotment under employee stock options, which fits the category of Share Issue/Capital Change (SHA).
2026-03-13 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.